The assay described aims to develop chemical activators of the enzyme glucocerebrosidase (GC) to treat Gaucher disease. GC breaks down beta-glucocerebroside to glucose and ceramide, but mutations in the GC gene can cause Gaucher disease. While inhibitors have been developed as chaperone therapy to stabilize altered proteins, they may have direct inhibitory effects. The assay uses patient tissue-derived N370S mutant GC and the enhanced MLPCN compound library for high-throughput screening to identify chemical activators of GC that may have better efficacy and safety profiles than inhibitors. Is the molecule effective to this assay?